Can discarded kidneys--or replacement parts from pigs--be prepped for use later as transplants? A regenerative medicine team at Wake Forest Baptist Medical Center says they've successfully completed two preclinical steps in that direction, raising the possibility that they can deliver a new source of these organs.
Celgene has stepped up with a deal to buy a $45 million chunk of Mesoblast's stock at a premium price in exchange for a front row seat on the Australian biotech's stem cell pipeline and a preferred spot at the bargaining table if it follows up with a licensing deal.
European and Japanese scientists have figured out how to "reset" human pluripotent stem cells, turning back the clock on cells so that they revert to their original state at the height of their development potential.
Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.
In 2010, Olympus bought Stryker's troubled OP-1 putty for $60 million, hoping to expand its market. Now, the Japanese maker of medical devices and cameras says it's selling the Lebanon, NH, plant where the putty is made at a bargain price--and if it can't make a deal it will close the facility.
Investors turned a cold shoulder to CryoLife Thursday after the Atlanta med tech and tissue processing company posted new guidance short of what Wall Street analysts had predicted.
Shire announced Friday it was selling the diabetic foot ulcer treatment to Canton, MA-based Organogenesis, which is not paying anything up front but could pay Shire up to $300 million if it meets sales targets up to 2018. With the deal, Organogenesis, which has its own foot ulcer product, gets the company's current 115,000-square-foot manufacturing plant in La Jolla, CA, but not the new facility.
Shire's once-promising foray into regenerative medicine has largely been a bust, and now the Irish company is handing its costly Dermagraft program to Organogenesis in exchange for little but milestone payments.
The regenerative medicine company Organogenesis is slashing jobs as part of its company-wide reorganization in the face of Medicare's decision to cut what it's paying for its wound-healing medicine Apligraf.
You can now count the Australian government as a major supporter of regenerative medicine research. Prime Minister Kevin Rudd has unveiled a $250 million public/private fund to back new work in the field, taking a stake in early-stage labor that will take years--and years--to pay off.